Neuro-oncology advances最新文献

{"title":"Evidence for inflammation in normal appearing brain regions in patients with growing sporadic vestibular schwannoma: a PET study","authors":"B. Alfaifi, R. Hinz, A. Jackson, Andrea M Wadeson, O. Pathmanaban, Charlotte L Hammerbeck-Ward, Scott A. Rutherford, Andrew T. King, Daniel Lewis, David J Coope","doi":"10.1093/noajnl/vdae094","DOIUrl":"https://doi.org/10.1093/noajnl/vdae094","url":null,"abstract":"\u0000 \u0000 \u0000 Non-auditory symptoms can be a prominent feature in patients with sporadic vestibular schwannoma (VS), but the cause of these symptoms is unknown. Inflammation is hypothesized to play a key role in the growth and symptomatic presentation of sporadic VS, and in this study we investigated through translocator protein (TSPO) PET whether inflammation occurred within the ‘normal appearing’ brain of such patients and its association with tumor growth.\u0000 \u0000 \u0000 \u0000 Dynamic PET datasets from fifteen patients with sporadic VS (8 static, 7 growing) who had been previously imaged using the TSPO tracer [11C](R)-PK11195 were included. Parametric images of [11C](R)-PK11195 binding potential (BPND) and the distribution volume ratio (DVR) were derived and compared across VS growth groups within both contralateral and ipsilateral grey (GM) and white-matter (WM) regions. Voxel-wise cluster analysis was additionally performed to identify anatomical regions of increased [11C](R)-PK11195 binding.\u0000 \u0000 \u0000 \u0000 Compared with static tumors, growing VS demonstrated significantly higher cortical (GM, 1.070 vs 1.031, p = 0.03) and whole brain (GM&WM,1.045 vs 1.006, p = 0.03) [11C](R)-PK11195 DVR values. Voxel-wise analysis supported the region-based analysis and revealed clusters of high TSPO binding within the precentral, postcentral, and prefrontal cortex in patients with growing VS.\u0000 \u0000 \u0000 \u0000 We present the first in vivo evidence of increased TSPO expression and inflammation within the brains of patients with growing sporadic VS. These results provide a potential mechanistic insight into the development of non-auditory symptoms in these patients and highlight the need for further studies interrogating the role of neuroinflammation in driving VS symptomatology.\u0000","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141369372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency","authors":"M. P. Nguyen, Damian Almiron Bonnin, Kanish Mirchia, William C Chen, Ezequiel Goldschmidt, S. Braunstein, Arie Perry, D. Raleigh, N. Oberheim Bush","doi":"10.1093/noajnl/vdae092","DOIUrl":"https://doi.org/10.1093/noajnl/vdae092","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141368802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo modelling recapitulates radiotherapy delivery and late-effect profile for childhood medulloblastoma","authors":"Jemma Castle, Gary Shaw, Dominic Weller, E. Fielder, T. Egnuni, Mankaran Singh, Roderick Skinner, T. von Zglinicki, Steven C. Clifford, Susan C Short, Satomi Miwa, Debbie Hicks","doi":"10.1093/noajnl/vdae091","DOIUrl":"https://doi.org/10.1093/noajnl/vdae091","url":null,"abstract":"\u0000 \u0000 \u0000 Medulloblastoma (MB) is the most common malignant paediatric brain tumour, with 5-year survival rates >70%. Cranial radiotherapy (CRT) to the whole-brain, with posterior fossa boost (PFB), underpins treatment for non-infants, however, radiotherapeutic insult to normal brain has deleterious consequences to neurocognitive and physical functioning, and causes accelerated ageing/frailty. Approaches to ameliorate radiotherapy-induced late-effects are lacking and a paucity of appropriate model systems hinders their development.\u0000 \u0000 \u0000 \u0000 We have developed a clinically-relevant in vivo model system that recapitulates the radiotherapy dose, targeting and developmental stage of childhood medulloblastoma. Consistent with human regimens, age-equivalent (postnatal days 35-37) male C57Bl/6J mice received CT image-guided CRT (human-equivalent 37.5 Gy EQD2, n=12) ± PFB (human-equivalent 48.7 Gy EQD2, n=12), via the small animal radiation research platform (SARRP) and were longitudinally assessed for >12 months.\u0000 \u0000 \u0000 \u0000 CRT was well tolerated, independent of PFB receipt. Compared to a sham-irradiated group (n=12), irradiated mice were significantly frailer following irradiation (frailty index; p=0.0002) and had reduced physical functioning; time to fall from a rotating rod (rotarod; p=0.026) and grip strength (p=0.006) were significantly lower. Neurocognitive deficits were consistent with childhood MB survivors; irradiated mice displayed significantly worse working memory (Y-maze; p=0.009) and exhibited spatial memory deficits (Barnes maze; p=0.029). Receipt of PFB did not induce a more severe late-effect profile.\u0000 \u0000 \u0000 \u0000 Our in vivo model mirrored childhood MB radiotherapy and recapitulated features observed in the late-effect profile of MB survivors. Our clinically-relevant model will facilitate both the elucidation of novel/target mechanisms underpinning MB late-effects and the development of novel interventions for their amelioration.\u0000","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141377688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of WHO grade and methylation class of aggressive meningiomas: Extraction of diagnostic information from infrared spectroscopic data","authors":"R. Galli, Franz Lehner, S. Richter, K. Kirsche, Matthias Meinhardt, Tareq A. Juratli, Achim Temme, M. Kirsch, Rolf Warta, C. Herold-Mende, F. Ricklefs, K. Lamszus, P. Sievers, Felix Sahm, I. Eyüpoglu, Ortrud Uckermann","doi":"10.1093/noajnl/vdae082","DOIUrl":"https://doi.org/10.1093/noajnl/vdae082","url":null,"abstract":"\u0000 \u0000 \u0000 Infrared (IR) spectroscopy allows intraoperative, optical brain tumor diagnosis. Here, we explored it as a translational technology for the identification of aggressive meningioma types according to both, the WHO CNS grading system and the methylation classes (MC).\u0000 \u0000 \u0000 \u0000 Frozen sections of 47 meningioma were examined by IR spectroscopic imaging and different classification approaches were compared to discern samples according to WHO grade or MC.\u0000 \u0000 \u0000 \u0000 IR spectroscopic differences were more pronounced between WHO grade 2 and 3 than between MC intermediate and MC malignant, although similar spectral ranges were affected. Aggressive types of meningioma exhibited reduced bands of carbohydrates (at 1024 cm-1) and nucleic acids (at 1080 cm-1), along with increased bands of phospholipids (at 1240 and 1450 cm-1). While linear discriminant analysis was able to discern spectra of WHO grade 2 and 3 meningiomas (AUC 0.89), it failed for MC (AUC 0.66). However, neural network classifiers were effective for classification according to both WHO grade (AUC 0.91) and MC (AUC 0.83), resulting in the correct classification of 21/23 meningiomas of the test set.\u0000 \u0000 \u0000 \u0000 IR spectroscopy proved capable of extracting information about the malignancy of meningiomas, not only according to the WHO grade, but also for a diagnostic system based on molecular tumor characteristics. In future clinical use, physicians could assess the goodness of the classification by considering classification probabilities and cross-measurement validation. This might enhance the overall accuracy and clinical utility, reinforcing the potential of IR spectroscopy in advancing precision medicine for meningioma characterization.\u0000","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141379395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival after Resection of Malignant Peripheral Nerve Sheath Tumors: introducing and validating a novel type-specific prognostic model","authors":"I. Acem, E. Steyerberg, Marta Spreafico, D. Grünhagen, D. Callegaro, Robert J Spinner, Courtney Pendleton, J. H. Coert, Rosalba Miceli, Giulia Abruzzese, U. Flucke, Willem-Bart M. Slooff, T. van Dalen, L. B. Been, H. Bonenkamp, M. Anten, Martinus P G Broen, Marc H A Bemelmans, J. Bramer, Gerard Schaap, A. Kievit, J. van der Hage, W. V. van Houdt, M. V. D. van de Sande, A. Gronchi, C. Verhoef, E. Martin","doi":"10.1093/noajnl/vdae083","DOIUrl":"https://doi.org/10.1093/noajnl/vdae083","url":null,"abstract":"\u0000 \u0000 \u0000 This study aimed to assess the performance of currently available risk calculators in a cohort of patients with malignant peripheral nerve sheath tumors (MPNST) and to create an MPNST-specific prognostic model including type-specific predictors for overall survival (OS).\u0000 \u0000 \u0000 \u0000 This is a retrospective multicenter cohort study of patients with MPNST from eleven secondary or tertiary centers in The Netherlands, Italy and the USA. All patients diagnosed with primary MPNST who underwent macroscopically complete surgical resection from 2000-2019 were included in this study. A multivariable Cox proportional hazard model for OS was estimated with pre-specified predictors (age, grade, size, NF-1 status, triton status, depth, tumor location and surgical margin). Model performance was assessed for the Sarculator and PERSARC calculators by examining discrimination (C-index) and calibration (calibration plots and observed-expected statistic; O/E-statistic). Internal-external cross-validation by different regions was performed to evaluate the generalizability of the model.\u0000 \u0000 \u0000 \u0000 A total of 507 patients with primary MPNSTs were included from 11 centers in 7 regions. During follow-up (median 8.7 years), 211 patients died. The C-index was 0.60 (95% CI 0.53-0.67) for both Sarculator and PERSARC. The MPNST-specific model had a pooled C-index of 0.69 (95%CI 0.65-0.73) at validation, with adequate discrimination and calibration across regions.\u0000 \u0000 \u0000 \u0000 The MPNST-specific MONACO model can be used to predict 3-, 5-, and 10-year OS in patients with primary MPNST who underwent macroscopically complete surgical resection. Further validation may refine the model to inform patients and physicians on prognosis and support them in shared decision-making.\u0000","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141386010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of intensity-modulated proton therapy in reducing radiation-induced lymphopenia in glioma patients.","authors":"Anindita Das, Jacinthlyn Sylvia, Ganapathy Krishnan, Pankaj Kumar Panda, Preethi Subramanyam, Roopesh Kumar, Rajendran Adhithyan, Sushama Patil, Dayananda Sharma, Rakesh Jalali","doi":"10.1093/noajnl/vdae088","DOIUrl":"10.1093/noajnl/vdae088","url":null,"abstract":"<p><strong>Background: </strong>Current standard management in adult grades 2-4 gliomas includes maximal safe resection followed by adjuvant radiotherapy (RT) and chemotherapy. Radiation-induced lymphopenia (RIL) has been shown to possibly affect treatment outcomes adversely. Proton beam therapy (PBT) may reduce the volume of the normal brain receiving moderate radiation doses, and consequently RIL. Our aim was to evaluate the incidence and severity of RIL during proton beam therapy (PBT).</p><p><strong>Methods: </strong>We identified patients with grades 2-4 glioma treated with PBT at our center between January 2019 and December 2021. We evaluated the incidence and severity of RIL from weekly complete blood count (CBC) data collected during PBT and compared it to the patients who were treated with photon-based RT (XRT) at our center during the same time.</p><p><strong>Results: </strong>The incidence of any degree of lymphopenia (48% in PBT, vs. 81.2% in XRT, <i>P</i> value = .001) and severe lymphopenia (8% in PBT, vs. 24.6% in XRT, <i>P</i> value = .093) were both significantly lesser in patients who received PBT. Severe RIL in patients receiving PBT was seen in only CNS WHO Gr-4 tumors. Mean whole brain V20GyE and V25GyE inversely correlated to nadir ALC and were both significantly lower with PBT. Patients with lymphopenia during PBT showed a trend toward poorer progression-free survival (<i>P</i> = .053) compared to those with maintained lymphocyte counts.</p><p><strong>Conclusions: </strong>Proton therapy seems to have a superior sparing of normal brain to moderate dose radiation than photon-based RT and reduces the incidence of lymphopenia. Glioma patients with lymphopenia possibly have worse outcomes than the ones with maintained lymphocyte counts.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11263926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging meningioma biology: Machine learning predicts integrated risk score in WHO grade 2/3 meningioma.","authors":"Olivia Kertels, Claire Delbridge, Felix Sahm, Felix Ehret, Güliz Acker, David Capper, Jan C Peeken, Christian Diehl, Michael Griessmair, Marie-Christin Metz, Chiara Negwer, Sandro M Krieg, Julia Onken, Igor Yakushev, Peter Vajkoczy, Bernhard Meyer, Daniel Zips, Stephanie E Combs, Claus Zimmer, David Kaul, Denise Bernhardt, Benedikt Wiestler","doi":"10.1093/noajnl/vdae080","DOIUrl":"10.1093/noajnl/vdae080","url":null,"abstract":"<p><strong>Background: </strong>Meningiomas are the most common primary brain tumors. While most are benign (WHO grade 1) and have a favorable prognosis, up to one-fourth are classified as higher-grade, falling into WHO grade 2 or 3 categories. Recently, an integrated risk score (IRS) pertaining to tumor biology was developed and its prognostic relevance was validated in a large, multicenter study. We hypothesized imaging data to be reflective of the IRS. Thus, we assessed the potential of a machine learning classifier for its noninvasive prediction using preoperative magnetic resonance imaging (MRI).</p><p><strong>Methods: </strong>In total, 160 WHO grade 2 and 3 meningioma patients from 2 university centers were included in this study. All patients underwent surgery with histopathological workup including methylation analysis. Preoperative MRI scans were automatically segmented, and radiomic parameters were extracted. Using a random forest classifier, 3 machine learning classifiers (1 multiclass classifier for IRS and 2 binary classifiers for low-risk and high-risk prediction, respectively) were developed in a training set (120 patients) and independently tested in a hold-out test set (40 patients).</p><p><strong>Results: </strong>Multiclass IRS classification had a test set area under the curve (AUC) of 0.7, mostly driven by the difficulties in clearly separating medium-risk from high-risk patients. Consequently, a classifier predicting low-risk IRS versus medium-/high-risk showed a very high test accuracy of 90% (AUC 0.88). In particular, \"sphericity\" was associated with low-risk IRS classification.</p><p><strong>Conclusion: </strong>The IRS, in particular molecular low-risk, can be predicted from imaging data with high accuracy, making this important prognostic classification accessible by imaging.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11217900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.","authors":"Ines Esparragosa Vazquez, Marc Sanson, Olivier L Chinot, Maxime Fontanilles, Romain Rivoirard, Laure Thomas-Maisonneuve, Stéphanie Cartalat, Emeline Tabouret, Romain Appay, Alice Bonneville-Levard, Amélie Darlix, David Meyronet, Marc Barritault, François Gueyffier, Laurent Remontet, Delphine Maucort-Boulch, Jérôme Honnorat, Caroline Dehais, François Ducray","doi":"10.1093/noajnl/vdae078","DOIUrl":"10.1093/noajnl/vdae078","url":null,"abstract":"<p><strong>Background: </strong>Based on preclinical studies showing that IDH-mutant (IDHm) gliomas could be vulnerable to PARP inhibition we launched a multicenter phase 2 study to test the efficacy of olaparib monotherapy in this population.</p><p><strong>Methods: </strong>Adults with recurrent IDHm high-grade gliomas (HGGs) after radiotherapy and at least one line of alkylating chemotherapy were enrolled. The primary endpoint was a 6-month progression-free survival rate (PFS-6) according to response assessment in neuro-oncology criteria. Pre-defined threshold for study success was a PFS-6 of at least 50%.</p><p><strong>Results: </strong>Thirty-five patients with recurrent IDHm HGGs were enrolled, 77% at ≥ 2nd recurrence. Median time since diagnosis and radiotherapy were 7.5 years and 33 months, respectively. PFS-6 was 31.4% (95% CI [16.9; 49.3%]). Two patients (6%) had an objective response and 14 patients (40%) had a stable disease as their best response. Median PFS and median overall survival were 2.05 and 15.9 months, respectively. Oligodendrogliomas (1p/19q codeleted) had a higher PFS-6 (53.4% vs. 15.7%, <i>P</i> = .05) than astrocytomas while an initial diagnosis of grade 4 astrocytoma tended to be associated with a lower PFS-6 compared to grade 2/3 gliomas (0% vs 31.4%, <i>P</i> = .16). A grade 2 or 3 treatment-related adverse event was observed in 15 patients (43%) and 5 patients (14%), respectively. No patient definitively discontinued treatment due to side effects.</p><p><strong>Conclusions: </strong>Although it did not meet its primary endpoint, the present study shows that in this heavily pretreated population, olaparib monotherapy was well tolerated and resulted in some activity, supporting further PARP inhibitors evaluation in IDHm HGGs, especially in oligodendrogliomas.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11157627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141297628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic ascertainment of primary central nervous system cancers in adolescents and young adults.","authors":"Douglas R Stewart","doi":"10.1093/noajnl/vdae048","DOIUrl":"10.1093/noajnl/vdae048","url":null,"abstract":"<p><p>Genomic ascertainment is the inversion of the traditional phenotype-first approach; with a \"genome-first\" approach, a cohort linked to electronic health records (EHR) undergoes germline sequencing (array, panel, exome, and genome) and deleterious variation of interest in a gene (or set of genes) are identified. Phenotype is then queried from the linked EHR and from call-back investigation and estimates of variant prevalence, disease penetrance, and phenotype can be determined. This should permit a better estimate of the full phenotypic spectrum, severity, and penetrance linked to a deleterious variant. For now, given the modest size, limited EHR, and age of participants in sequenced cohorts, genomic ascertainment approaches to investigate cancer in children and young adults will likely be restricted to descriptive studies and complement traditional phenotype-first work. Another issue is the ascertainment of the cohort itself: Participants need to survive long enough to enroll. Not accounting for this may lead to bias and incorrect estimates of variant prevalence. Adult-focused cohorts with EHR extending back into childhood, linked to cancer registries, and/or studies that permit recontact with participants may facilitate genomic ascertainment in pediatric cancer research. In summary, genomic ascertainment in pediatric primary brain cancer research remains largely untapped and merits further investigation.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11125399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141156028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SNO pediatric molecular tumor board series: Successful beginnings and future directions.","authors":"Holly B Lindsay, Craig Erker, Suzanne Laughlin, Annie Huang","doi":"10.1093/noajnl/vdae076","DOIUrl":"https://doi.org/10.1093/noajnl/vdae076","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11154129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141285764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}